News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
《大行》瑞銀下調藥明生物(02269.HK)今明兩年每股盈利預測 微降目標價至49.3元
瑞銀研報指出，藥明生物(02269.HK)去年下半年業績符合預期，收入按年增長17.2%至118億元人民幣(下同)，股東應佔溢利按年增長38.3%至26億元。 毛利率提升5個百分點至46%，主要受營運效率改善、授權收入增加及設施使用率提升帶動。報告提及，藥明生物管理層預期2026年收入按年增長13%至17%，該行估算其高增長與預期相符，但考慮到潛在匯率影響及...
Reset
Send
The window will close in 5 seconds
《大行》瑞銀下調藥明生物(02269.HK)今明兩年每股盈利預測 微降目標價至49.3元
Close
Recommend
9
Positive
8
Negative
12
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

瑞銀研報指出，藥明生物(02269.HK)  +0.120 (+0.344%)    Short selling $282.70M; Ratio 73.681%   去年下半年業績符合預期，收入按年增長17.2%至118億元人民幣(下同)，股東應佔溢利按年增長38.3%至26億元。 毛利率提升5個百分點至46%，主要受營運效率改善、授權收入增加及設施使用率提升帶動。

報告提及，藥明生物管理層預期2026年收入按年增長13%至17%，該行估算其高增長與預期相符，但考慮到潛在匯率影響及2025年下半年業績，瑞銀下調集團今明兩年每股盈利預測4%至5%。將目標價由51.6港元微降至49.3港元，相當預測今明兩年市盈率各33倍及27倍，維持「買入」評級。(hc/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.